MX343490B - Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos. - Google Patents

Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.

Info

Publication number
MX343490B
MX343490B MX2013011716A MX2013011716A MX343490B MX 343490 B MX343490 B MX 343490B MX 2013011716 A MX2013011716 A MX 2013011716A MX 2013011716 A MX2013011716 A MX 2013011716A MX 343490 B MX343490 B MX 343490B
Authority
MX
Mexico
Prior art keywords
antibodies
antibody fragments
neutralizing antibodies
human cytomegalovirus
relates
Prior art date
Application number
MX2013011716A
Other languages
English (en)
Inventor
Lanzavecchia Antonio
Macagno Annalisa
Original Assignee
Inst For Res In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343490(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst For Res In Biomedicine filed Critical Inst For Res In Biomedicine
Publication of MX343490B publication Critical patent/MX343490B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A01D34/71—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis with means for discharging mown material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D2101/00—Lawn-mowers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un proceso para producir un derivado particulado de celulosa al moler y secar un derivado de celulosa húmeda utilizando una corriente de gas de secado, que comprende los pasos de A) proveer un derivado de celulosa húmeda que tiene un contenido de humedad desde 60 hasta 95 por ciento, tomando como base el peso total del derivado de celulosa húmeda, B) moler y secar parcialmente el derivado de celulosa húmeda en un molino de impacto con barrido de gases al cual se alimenta una primera corriente de gas de secado; y C) poner en contacto el derivado de celulosa molida y parcialmente seca con una segunda corriente de gas de secado fuera del molino de impacto con barrido de gases, en donde el derivado de celulosa está suspendido en la cantidad o en por lo menos una porción de la primera corriente de gas de secado que sale del molino de impacto con barrido de gases cuando el derivado de celulosa se pone en contacto con la segunda corriente de gas de secado fuera del molino de impacto con barrido de gases para producir el derivado particulado de celulosa.
MX2013011716A 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos. MX343490B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8133408P 2008-07-16 2008-07-16
PCT/IB2009/006641 WO2010007533A2 (en) 2008-07-16 2009-07-15 Human cytomegalovirus neutralizing antibodies and use thereof

Publications (1)

Publication Number Publication Date
MX343490B true MX343490B (es) 2016-11-08

Family

ID=41550776

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2013011719A MX343250B (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
MX2011000543A MX2011000543A (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
MX2013011720A MX338067B (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
MX2013011716A MX343490B (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
MX2013011718A MX340315B (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2013011719A MX343250B (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
MX2011000543A MX2011000543A (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
MX2013011720A MX338067B (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013011718A MX340315B (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.

Country Status (30)

Country Link
US (21) US8124093B2 (es)
EP (3) EP3178845A1 (es)
JP (5) JP5422649B2 (es)
KR (1) KR101356350B1 (es)
CN (3) CN102203133B (es)
AU (1) AU2009272284C1 (es)
BR (1) BRPI0916443A2 (es)
CA (2) CA3022196A1 (es)
CL (3) CL2011000084A1 (es)
CO (1) CO6351801A2 (es)
CR (2) CR20160355A (es)
CU (1) CU23953B1 (es)
DK (2) DK3009449T3 (es)
EA (1) EA031177B1 (es)
EC (2) ECSP11010826A (es)
ES (2) ES2654543T3 (es)
GT (4) GT201100011BA (es)
HN (1) HN2011000161A (es)
IL (7) IL210356A (es)
MA (1) MA32561B1 (es)
MX (5) MX343250B (es)
NZ (5) NZ603499A (es)
PE (7) PE20140882A1 (es)
PH (1) PH12015500782A1 (es)
PL (2) PL3009449T3 (es)
PT (2) PT2352759T (es)
SG (3) SG10201706350PA (es)
UA (1) UA106354C2 (es)
WO (1) WO2010007533A2 (es)
ZA (1) ZA201600335B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8124093B2 (en) * 2008-07-16 2012-02-28 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
NZ600974A (en) 2009-12-23 2014-08-29 4Antibody Ag Binding members for human cytomegalovirus
CA2839420C (en) * 2010-06-16 2023-06-13 Lawrence M. Kauvar High affinity human antibodies to human cytomegalovirus (cmv) gb protein
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
CN103313727B (zh) * 2010-09-29 2015-07-22 弗·哈夫曼-拉罗切有限公司 抗体组合物及使用方法
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
BR112014024023A2 (pt) * 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
ES2719720T3 (es) 2012-07-27 2019-07-12 Hope City Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
HUE057432T2 (hu) 2015-04-07 2022-05-28 Alector Llc Anti-sortilin antitestek és ezek alkalmazási módjai
EP3347045A4 (en) 2015-09-10 2019-08-28 City of Hope MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
CN105296588A (zh) * 2015-10-16 2016-02-03 常州市第一人民医院 一种检测肾移植患者在术后感染巨细胞病毒危害程度的方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
WO2017153954A1 (en) 2016-03-11 2017-09-14 Pfizer Inc. Human cytomegalovirus gb polypeptide
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
EP3455251A4 (en) * 2016-05-09 2020-04-22 Icahn School of Medicine at Mount Sinai WIDE-NEUTRALIZING ANTIBODIES AGAINST HUMAN CYTOMEGALOVIRUS (HCMV) AND METHOD FOR USE THEREOF
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
EP3497232A1 (en) 2016-08-12 2019-06-19 Streck, Inc. Molecular reference controls
CN106519027B (zh) * 2016-11-11 2019-09-17 深圳先进技术研究院 抗h7n9全人源单克隆抗体5j13及其制法与应用
US11484570B2 (en) 2017-04-14 2022-11-01 University Of Massachusetts Targeting cell tropism receptors to inhibit cytomegalovirus infection
EP3612550B1 (en) 2017-04-19 2025-06-18 GlaxoSmithKline Biologicals S.A. Modified cytomegalovirus proteins and stabilized complexes
CN107325178A (zh) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用
HUE068517T2 (hu) 2017-10-19 2024-12-28 Streck Llc A hemolízis és a véralvadás szabályozására, valamint az extracelluláris vezikulák stabilizálására szolgáló készítmények
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
RS64034B1 (sr) 2018-07-13 2023-04-28 Alector Llc Anti-sortilin antitela i načini njihove upotrebe
MX2021004273A (es) 2018-10-17 2021-12-10 Glaxosmithkline Biologicals Sa Proteinas de citomegalovirus modificadas y complejos estabilizados.
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
US20220119502A1 (en) * 2019-02-28 2022-04-21 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
CN112898414B (zh) * 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
EP4126931A1 (en) * 2020-03-27 2023-02-08 GlaxoSmithKline Biologicals S.A. Hcvm pentamer binding antibodies
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CA3230585A1 (en) * 2021-09-03 2023-03-09 Domenico Tortorella Anti-hcmv antibodies and antigen-binding fragments thereof
CN118459574B (zh) * 2022-10-21 2025-06-17 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0198086B1 (en) 1984-09-28 1991-01-16 Teijin Limited Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0248909B1 (en) 1985-12-06 1994-08-17 Teijin Limited Anticytomegaloviral human monoclonal antibody and process for its preparation
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (en) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Monoclonal antibodies specific to cytomegalovirus glycoprotein
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
ES2125248T3 (es) 1992-04-10 1999-03-01 Thomas Totterman Metodo de deteccion de una infeccion cmv.
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
AU681115B2 (en) 1993-01-21 1997-08-21 Erna Moller Prevention and treatment of cytomegalovirus using aminopeptidase
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
JPH08506325A (ja) 1993-01-28 1996-07-09 サンド ファーマスーティカル コーポレーション サイトメガロウイルスに対するヒトモノクローナル抗体
AU6777594A (en) 1993-04-30 1994-11-21 Scripps Research Institute, The Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (de) 1994-07-26 1997-01-15 Biotest Ag Polypeptide und Fusionsproteine bestehend aus dem UL 57 Leserahmen bzw. dem C-terminalen Bereich des Tegumentproteins pp150 aus HCMV, entsprechende Oligonucleotide und Nachweis reagentien
US5502652A (en) 1994-08-24 1996-03-26 Hoggatt; Austin C. Method and apparatus for measuring heat transfer in small diameter pipes using acoustic signals
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
DE69716305T2 (de) 1996-07-12 2003-06-26 Organon Teknika B.V., Boxtel Peptidereagenz zum nachweis von humanem cytomegalovirus (cmv)
CA2263316A1 (en) 1996-08-14 1998-02-19 Klara Berencsi Methods and compositions for preventing or retarding the development of atherosclerotic lesions
US7504493B2 (en) * 1997-01-23 2009-03-17 The John Hopkins University Characterization of the yeast transcriptome
WO1998033892A1 (en) 1997-01-30 1998-08-06 Cedars-Sinai Medical Center Establishment of hhv-8+ lymphoma cell line, virus produced, antibody, diagnostic method and kit for detecting hhv-8 infection
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
EP0996730A1 (en) 1997-07-18 2000-05-03 Connaught Laboratories Limited Nucleic acid vaccines encoding g protein of respiratory syncytial virus
US20030180257A1 (en) 1997-11-14 2003-09-25 Mark Parrington Alphavirus vectors for paramyxovirus vaccines
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
IL138033A0 (en) 1998-03-12 2001-10-31 Genentech Inc Method of preventing the death of retinal neurons and treating ocular diseases
EP1091763B1 (de) 1998-06-29 2003-09-17 Wolfgang Bergter Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002066629A2 (en) 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
CN1188427C (zh) * 2001-12-07 2005-02-09 暨南大学 检测hcmv抗体的重组嵌合肽抗原及其产生方法
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
IL164326A0 (en) 2002-04-01 2005-12-18 Agensys Inc Nucleic acid and corresponding protein entitled 238p1b2 and pharmaceutical compositions containing the same
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
TWI270088B (en) 2002-11-29 2007-01-01 Furukawa Electric Co Ltd Insulated wire and resin dispersion
RU2239453C2 (ru) 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
CN1445243A (zh) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 抗人巨细胞病毒人源中和性基因工程Fab抗体
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20040228842A1 (en) 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
US20060216302A1 (en) 2003-02-28 2006-09-28 Robert Root-Bernstein Immunological markers
JP5160887B2 (ja) 2004-06-21 2013-03-13 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
CA2573090A1 (en) 2004-07-09 2006-01-19 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Differences in intestinal gene expression profiles
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
DE602005027258D1 (de) 2005-03-14 2011-05-12 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
KR101280096B1 (ko) 2005-06-29 2013-06-28 컴퓨메딕스 리미티드 전도성 브리지를 포함하는 센서 어셈블리
JP5142458B2 (ja) * 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
KR101508945B1 (ko) 2005-12-16 2015-04-08 리보박스 바이오테크놀로지즈 에스아 불멸화 항체분비 세포를 수득하는 방법
JPWO2007094423A1 (ja) 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
MX2008014722A (es) 2006-05-19 2011-04-15 Teva Pharma Proteinas de fusion, usos de las mismas y procesos para producir las mismas.
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ES2363992T3 (es) 2006-12-15 2011-08-22 Ribovax Biotechnologies Sa Anticuerpos frente a citomegalovirus humano (cmvh).
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
WO2008120203A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
EP2190876A1 (en) 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antibodies against human cytomegalovirus (hcmv)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
US8124093B2 (en) * 2008-07-16 2012-02-28 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
JP5475774B2 (ja) 2008-07-16 2014-04-16 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用

Also Published As

Publication number Publication date
PT2352759T (pt) 2018-01-08
US20210087257A1 (en) 2021-03-25
EA031177B1 (ru) 2018-11-30
BRPI0916443A2 (pt) 2017-10-31
ECSP11010827A (es) 2011-07-29
EP3009449A1 (en) 2016-04-20
NZ603499A (en) 2014-05-30
IL232862A (en) 2016-06-30
GT201100011BA (es) 2017-09-14
JP5807050B2 (ja) 2015-11-10
EP2352759B1 (en) 2017-11-01
EP2352759A2 (en) 2011-08-10
IL232863A0 (en) 2014-07-31
MX2011000543A (es) 2011-04-27
ES2682596T3 (es) 2018-09-21
PE20141432A1 (es) 2014-10-18
US8603480B2 (en) 2013-12-10
IL238421A (en) 2016-06-30
JP2015145412A (ja) 2015-08-13
WO2010007533A3 (en) 2010-08-12
US20160145319A1 (en) 2016-05-26
US9796771B2 (en) 2017-10-24
US9371372B2 (en) 2016-06-21
CA2730776A1 (en) 2010-01-21
CU23953B1 (es) 2013-10-29
PE20141435A1 (es) 2014-10-22
PL3009449T3 (pl) 2018-09-28
CA2730776C (en) 2018-12-11
PE20141434A1 (es) 2014-10-22
PL2352759T3 (pl) 2018-04-30
US20150353627A1 (en) 2015-12-10
US20170334972A1 (en) 2017-11-23
US20100092481A1 (en) 2010-04-15
AU2009272284C1 (en) 2014-05-15
SG10201706350PA (en) 2017-09-28
IL232862A0 (en) 2014-07-31
IL238421A0 (en) 2015-06-30
US20170129940A1 (en) 2017-05-11
CN102203133A (zh) 2011-09-28
US20170081391A1 (en) 2017-03-23
IL232864A (en) 2016-07-31
US20130022618A1 (en) 2013-01-24
IL210356A0 (en) 2011-03-31
NZ707788A (en) 2016-08-26
US9127049B2 (en) 2015-09-08
PE20110413A1 (es) 2011-06-25
PE20140882A1 (es) 2014-07-25
PH12015500782A1 (en) 2015-12-14
US20160096880A1 (en) 2016-04-07
US20200017575A1 (en) 2020-01-16
US20180371062A1 (en) 2018-12-27
US9803000B1 (en) 2017-10-31
US20160280770A1 (en) 2016-09-29
MA32561B1 (fr) 2011-08-01
US20120128691A1 (en) 2012-05-24
US8765132B2 (en) 2014-07-01
MX340315B (es) 2016-07-06
DK3009449T3 (en) 2018-08-06
GT201100011CA (es) 2017-09-14
CR20110091A (es) 2011-06-24
CN103980363B (zh) 2017-04-12
US9527902B2 (en) 2016-12-27
SG191699A1 (en) 2013-07-31
AU2009272284A1 (en) 2010-01-21
US20130302350A1 (en) 2013-11-14
JP2017055765A (ja) 2017-03-23
US20170129939A1 (en) 2017-05-11
KR101356350B1 (ko) 2014-01-27
EA201170205A1 (ru) 2011-08-30
PT3009449T (pt) 2018-09-28
NZ619953A (en) 2015-06-26
MX338067B (es) 2016-04-01
CR20160355A (es) 2016-10-11
AU2009272284B2 (en) 2012-04-05
US20140193428A1 (en) 2014-07-10
US20110268746A1 (en) 2011-11-03
US20160280769A1 (en) 2016-09-29
UA106354C2 (ru) 2014-08-26
WO2010007533A9 (en) 2017-08-10
US9796772B2 (en) 2017-10-24
CL2014001293A1 (es) 2014-12-05
US20120128692A1 (en) 2012-05-24
US8124093B2 (en) 2012-02-28
CL2016001340A1 (es) 2016-10-28
US9221897B2 (en) 2015-12-29
US8287870B2 (en) 2012-10-16
JP6345753B2 (ja) 2018-06-20
CN103980363A (zh) 2014-08-13
ZA201600335B (en) 2017-11-29
IL232865A0 (en) 2014-07-31
CL2011000084A1 (es) 2011-07-01
NZ591056A (en) 2013-02-22
CU20110009A7 (es) 2012-06-21
HN2011000161A (es) 2014-06-09
JP2011527902A (ja) 2011-11-10
IL232863A (en) 2016-06-30
HK1220981A1 (en) 2017-05-19
US9249213B2 (en) 2016-02-02
US20140205615A1 (en) 2014-07-24
US9491906B2 (en) 2016-11-15
JP6703037B2 (ja) 2020-06-03
GT201100011DA (es) 2017-09-20
IL232861A (en) 2016-06-30
ES2654543T3 (es) 2018-02-14
CN106924729B (zh) 2021-03-02
US10414817B2 (en) 2019-09-17
JP5422649B2 (ja) 2014-02-19
IL232865A (en) 2016-07-31
US20180086819A1 (en) 2018-03-29
CO6351801A2 (es) 2011-12-20
KR20110052585A (ko) 2011-05-18
DK2352759T3 (en) 2017-12-18
PE20141433A1 (es) 2014-10-19
US8435524B2 (en) 2013-05-07
NZ603498A (en) 2014-02-28
IL232861A0 (en) 2014-07-31
IL210356A (en) 2015-06-30
GT201100011AA (es) 2017-09-14
JP2018139611A (ja) 2018-09-13
IL232864A0 (en) 2014-07-31
EP3009449B1 (en) 2018-06-06
US9725502B2 (en) 2017-08-08
JP6062477B2 (ja) 2017-01-18
SG10201608381SA (en) 2016-11-29
WO2010007533A2 (en) 2010-01-21
US8298539B2 (en) 2012-10-30
CN102203133B (zh) 2015-01-07
US10040845B2 (en) 2018-08-07
CA3022196A1 (en) 2010-01-21
JP2014087337A (ja) 2014-05-15
US9365636B1 (en) 2016-06-14
PE20141398A1 (es) 2014-10-18
ECSP11010826A (es) 2011-07-29
CN106924729A (zh) 2017-07-07
US10889632B2 (en) 2021-01-12
EP3178845A1 (en) 2017-06-14
MX343250B (es) 2016-10-31

Similar Documents

Publication Publication Date Title
PH12015500782A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
MY161200A (en) Human cytomegalovirus neutralising antibodies and use thereof
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
IN2014KN02933A (es)
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ592054A (en) Dengue virus neutralizing antibodies and uses thereof
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
MY160590A (en) Cd127 binding proteins
EP4338754A3 (en) Antigen binding proteins
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
WO2010010467A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
PH12013500333A1 (en) Antibodies for epidermal growth factor receptor 3 (her3)
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
MY170404A (en) Antigen binding proteins
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
WO2012022734A3 (en) Anti-icam-1 antibodies and methods of use
TN2010000621A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
WO2006123122A3 (en) Psk- i and its modulators for the treatment/diagnosis of cancer